SGLT2 inhibitors may be useful for patients with NAFLD, but because they have only been introduced in the market in 2016, the long-term outcomes of their use in chronic liver disease have not yet been reported (Figure 1). Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.